GH Research (GHRS) Cash from Financing Activities (2021 - 2025)
GH Research's (GHRS) quarterly Cash from Financing Activities came in at -$68000.0 in Q4 2025, down 15.25% year-on-year from -$80240.0 in Q4 2024, and down 3.03% quarter-over-quarter from -$66000.0 in Q3 2025.
GH Research (GHRS) Cash from Financing Activities (2021 - 2025) Analysis & Trends
GH Research's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at -$68000.0 for Q4 2025.
- On a quarterly basis, Cash from Financing Activities fell 15.25% year-over-year to -$68000.0 in Q4 2025; TTM through Dec 2025 was $139.7 million, a 46037.83% increase from a year earlier, with the FY2025 full-year figure at $139.7 million, up 46037.83% from the prior year.
- Cash from Financing Activities declined to -$68000.0 in Q4 2025 per GHRS's latest filing, from -$66000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $286.6 million in Q4 2022 and bottomed at -$2.6 million in Q3 2021.
- The 5-year median for Cash from Financing Activities is -$68000.0 (2025), against an average of $32.7 million.
- Biggest YoY gain for Cash from Financing Activities was 198491.55% in 2025; the steepest drop was 841.23% in 2025.
- Year by year, Cash from Financing Activities stood at -$171000.0 in 2021, then jumped by 167712.87% to $286.6 million in 2022, then sank by 100.02% to -$70000.0 in 2023, then climbed by 15.71% to -$59000.0 in 2024, then fell by 15.25% to -$68000.0 in 2025.
- Per Business Quant, the three latest GHRS Cash from Financing Activities figures stand at -$68000.0 (Q4 2025), -$66000.0 (Q3 2025), and -$1.1 million (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 238.74 Mn |
| 10 | GH Research | 1.65 Bn | 1.65 Bn | - | -68,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -68,000.00 |
| Dec 31, 2025 | -68,000.00 |
| Sep 30, 2025 | -66,000.00 |
| Sep 30, 2025 | -66,000.00 |
| Jun 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Mar 31, 2025 | 140.86 Mn |
| Mar 31, 2025 | 140.86 Mn |
| Dec 31, 2024 | -59,000.00 |
| Dec 31, 2024 | -59,000.00 |
| Sep 30, 2024 | -60,000.00 |
| Sep 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -114,000.00 |
| Jun 30, 2024 | -114,000.00 |
| Mar 31, 2024 | -71,000.00 |
| Mar 31, 2024 | -71,000.00 |
| Mar 31, 2023 | -70,000.00 |
| Mar 31, 2023 | -70,000.00 |
| Dec 31, 2022 | 286.62 Mn |
| Dec 31, 2022 | 286.62 Mn |